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Background: Elevated total plasma homocysteine (tHcy) in humans is associated with cardiovascular disease but
prevention trials have failed to confirm causality. Reported reasons for this association have been that
homocysteine and its major genetic determinant methylenetetrahydrofolate reductase (MTHFR) may have an effect
on HDL and Apolipoprotein (Apo) A1 levels. We wanted to study if tHcy and its major determinants were
correlated with Apo A1 levels in a large population without folate fortification.
Methods: This study was a prospective incident nested case-referent study within the Northern Sweden Health and
Disease Study Cohort (NSHDSC), including 545 cases with first myocardial infarction and 1054 matched referents,
median age at inclusion was 59 years. Univariate and multiple regression analyzes was used to study the
associations between apolipoproteins Apo A1 and B, tHcy, folate and vitamin B12 in plasma as well as MTHFR
polymorphisms 677C>T and 1298A>C.
Results: Apo A1 and Apo B were strongly associated with the risk of a first myocardial infarction. tHcy was not
associated with Apo A1 levels. Instead, folate had an independent positive association with Apo A1 levels in
univariate and multiple regression models. The associations were seen in all men and women, among referents but
not among cases. MTHFR polymorphisms had no clear effect on Apo A1 levels.
Conclusions: Analyzing over 1500 subjects we found an independent positive association between plasma folate
(major dietary determinant of tHcy) and Apo A1 levels among those who later did not develop a first myocardial
infarction. No association was seen between tHcy and Apo A1.
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Hyperhomocysteinemia has been claimed to be a risk factor
for cardiovascular disease. Evidence for this has come from
meta-analysis based on several epidemiological studies and
also from prospective studies [1-7]. The results of random-
ized trials with homocysteine lowering treatment have
failed to show that homocysteine is a causal risk factor
[8-10]. This raises the possibility that homocysteine levels
could be associated with another casual risk factor.* Correspondence: elisabet.soderstrom@medbio.umu.se
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distribution, and reproduction in any mediumSeveral different mechanisms how hyperhomocysteinemia
can lead to atherosclerosis are described, such as inflamma-
tion, oxidative stress and enhanced lipogenesis [11,12].
Apolipoprotein A1 (Apo A1) is the major protein
component of HDL and is believed to have an
atheroprotective role through several mechanisms;
one of them is reverse cholesterol transport [13-15].
In epidemiological studies elevated tHcy has been
negatively associated with high density lipoprotein
(HDL) cholesterol [16-21], and more recently with Apo
A1 [20,22-25]. The methylenetetrahydrofolate (MTHFR)
polymorphism which has a major impact on tHcy levels
[26] has also been reported to have an influence on Apo A1
levels [21,27]. Cell studies have shown that mRNAntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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MTHFR-polymorphism [27]. This would suggest that
hyperhomocysteinemia may be associated with an
increased risk of atherosclerosis due to decreased
expression of Apo A1 [16,23,27-29]. Some studies
have failed to demonstrate an association between
Apo A1 and / or HDL with tHcy [30-33] and MTHFR
polymorphisms [22,31].
Only a few reports have been published regarding the
relationship between folate and Apo A1. In a Norwegian
case–control study with 107 patients with acute myocardial
infarction (MI), whole blood folate correlated positively and
tHcy negatively with Apo A1 and HDL [34]. In a larger
study in men, no correlation with folate was seen for
Apo A1 or HDL [31]. A small quasi-experimental
study including 32 patients with type 2 diabetes, where
the patients had a tomato intake (200 g per day), which is
a rich source of folate, showed after 8 weeks a significant
increase of Apo A1 although tHcy did not change [35].
The aim of this study was to investigate if tHcy and its
major determinants folate, vitamin B12 and MTHFR
polymorphism are correlated with Apo A1 levels in over
1500 subjects, without folate fortification, including both
men and women and to see if this correlation was
present among those who did and did not develop a first
myocardial infarction. Using multiple regression models,
an independent positive association was seen between
plasma folate and Apo A1 levels among those who later
did not develop a first myocardial infarction.
Results
The baseline characteristics including the apolipoprotein
levels and the MTHFR 677 C>T and 1298 A>C
distribution, are presented in Table 1. The plasma
concentrations of total homocysteine and Apo B
were significantly higher and the Apo A1 concentrations
lower, in cases compared to referents. The MTHFR
genotypes for both cases and referents were in Hardy-
Weinberg equilibrium. ORs for the quartiles of apolipo-
proteins and Apo B/Apo A1 ratio are shown in Table 2.
Apo A1 showed a negative association with the risk of a
first MI among men. Among women Apo A1 did not show
significant relations in the adjusted models. After adjusting
Apo A1 with folate levels the findings remained significant.
For Apo B positive associations were seen in all models.
Apo B/Apo A1 ratio had a positive association both among
men and women in the unadjusted model, though stronger
among women. After adjustment (model including
diabetes) OR increased among women but the opposite
effect were seen among men.
Determinants of Apo A1
The correlations of clinical data, analytes and MTHFR
genotypes with Apo A1 in univariate linear regressionanalysis for men and women separately are seen in
Table 3. tHcy in plasma was not associated with Apo
A1 levels. Subset analysis of women defined as postmeno-
pausal (age 56 years and older) showed the same significant
associations as for all women. The same was seen for
women below 56 years.
Among all men and male referents Vitamin B12 and
folate levels were associated with Apo A1.
Univariate analyses were performed in subgroups
based on fasting status. Only 3.6% (n=41) of the men
had fasted for less than 4 hours. An association was seen
between homocysteine and Apo A1 in this non-fasting
group. But among the male fasting subjects no significant
associations were seen for tHcy with Apo A1. In contrast,
folate remained significantly associated with Apo A1
among men that had fasted more than 8 hours.
Among women no significant association was seen for
tHcy and Apo A1 in the subgroups. For folate and
Apo A1 a significant association was seen in the
fasting group of 4–8 hours.
Regarding MTHFR genotypes, no associations with
apolipoproteins were seen in all men and women
respectively, but among male referents, a negative
association was found between Apo A1 and MTHFR
677 in a recessive model.
Multiple regression analysis for the association with
ApoA1 is presented in Table 4 and for subgroups in
Table 5. Among all men, Apo A1 was associated with
BMI, age, systolic blood pressure, vitamin B12, folate,
creatinine and CRP. The associations between Apo A1
and analytes were consistent in male referents, except
for creatinine. For male cases Apo A1 were associated
with creatinine and CRP. The association between Apo
A1 and clinical data were consistent in male cases but
only for BMI in male referents. Among all women and
female referents, folate and CRP were associated with Apo
A1. No associations were seen for female cases. Adding
homocysteine to the multiple models did not change the
results for men, but significance was lost for folate among
women. Among all men, R2 of the total model was 0.144,
i.e. it explains 14.4% of the variation in Apo A1 levels.
Clinical data and plasma variables had R2 values 0.085 and
0.074 respectively. Among all women, corresponding
R2 values were 0.106, 0.066 and 0.065.
Determinants of Apo B
The correlations of clinical data, analytes and MTHFR
genotypes with Apo B in univariate linear regression
analysis for men and women separately are seen in
Table 6. For tHcy there was an association with Apo B
levels among all women and female referents and among
the same, folate was negatively associated with Apo B.
tHcy and folate did not remain significant in a subset
analyses of women defined as postmenopausal (age 56
Table 1 Baseline characteristics of myocardial infarction cases and referents
Men Women
All Cases Referents All Cases Referents
N N N N
Age at inclusion, years 53.4 ± 7.7 387 53.6 ± 7.7a 752 53.4 ± 7.7 58.2 ± 7.5 158 58.3 ± 7.5a 302 58.1 ± 7.5
Lag time to MI, years n.a. 387 4.3 ± 2.5 n.a. n.a. n.a. 158 3.4 ± 2.4 n.a. n.a.
BMI, kg/m2 26.3 ± 3.6 375 27.1 ± 3.7b 727 25.9 ± 3.4 26.3 ± 4.7 86 26.7 ± 4.7 170 26.1 ± 4.8
Diabetesc 7.2 361 11.1d 695 5.2 7.7 78 9.0 156 7.1
Hypertensionc 50.5 373 62.2b 721 44.4 57.4 84 72.6d 165 49.7
Current smokingc 24.9 365 38.4b 723 18.1 28.3 152 46.7b 297 18.9
Alcohol intake, g/day 5.5 ± 5.1 170 4.6 ± 4.6d 367 5.9 ± 5.3 2.41 ± 2.70 35 2.4 ± 2.4 78 2.4 ± 2.8
Apo A1, g/L 1.40 ± 0.21 381 1.35 ± 0.21b 734 1.42 ± 0.21 1.57 ± 0.26 155 1.51 ± 0.23b 295 1.60 ± 0.27
Apo B, g/L 1.21 ± 0.27 381 1.29 ± 0.28b 734 1.17 ± 0.26 1.22 ± 0.29 155 1.29 ± 0.26b 295 1.18 ± 0.30
Apo B/ Apo A1 ratio 0.89 ± 0.25 381 0.98 ± 0.26b 734 0.84 ± 0.23 0.80 ± 0.23 155 0.87 ± 0.2b 295 0.75 ± 0.22
Homocysteine, μmol/L 11.41 ± 4.60 370 11.87 ± 3.83e 700 11.16 ± 4.94 10.74 ± 4.36 155 12.19 ± 6.21b 293 9.98 ± 2.67
Folate, nmol/L 9.69 ± 4.82 369 8.83 ± 4.45b 700 10.14 ± 4.94 11.77 ± 10.14 155 10.64 ± 7.70 293 12.37 ± 11.19
B12, pmol/L 331 ± 158 370 329 ± 148 700 332 ± 162 359 ± 207 155 359 ± 260 293 359 ± 173
MTHFR 677C>T n.a. 366 n.a. 693 n.a. n.a. 148 n.a. 278 n.a.
CC 50.8 185 50.5 353 50.9 50.7 80 54.1 136 48.9
CT 40.6 150 41.0 280 40.4 39.2 55 37.2 112 40.3
TT 8.6 31 8.5 60 8.7 10.1 13 8.8 30 10.8
MTHFR 1298A>C n.a. 367 n.a. 692 n.a. n.a. 150 n.a. 278 n.a.
AA 39.0 136 37.1 277 40.0 43.9 62 41.3 126 45.3
AC 48.3 189 51.5 323 46.7 42.8 66 44.0 117 42.1
CC 12.7 42 11.4 92 13.3 13.3 22 14.7 35 12.6
Cases and referents were compared by T-test for continues variables and by Chi-square test for independence for categorical variables. Significant p-values are
shown in superscript letters: amatched; bp<0.001; cFor definition see method section; dp<0.01; ep<0.05; n.a. = not applicable.
Presented as mean ± SD for continuous variables, and as proportions/percent for non-continuous variables.
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status showed no significant associations for tHcy and
Apo B among men. In women the significant association
remained in the non-fasting group. For folate and Apo B
no significant association was seen in the subgroups
among men. In women significant associations remained
in the non-fasting group and in the group that had
fasted 4–8 hours.
Regarding MTHFR genotypes, no associations with
apolipoproteins were seen in all men and women
respectively, but in male referents between Apo B and
MTHFR 1298A>C and with 1298 in a recessive model.
Multiple regression analysis for the association with Apo
B is presented in Table 4 and for subgroups in Table 7.
For Apo B an association was seen in all men for BMI,
age and albumin. The same was seen for male referents
but among male cases an association was seen only for
albumin. For all women an association was seen with
age, systolic blood pressure, smoking and creatinine. In
female referents positive association was seen for
creatinine and all clinical data, except BMI. Among
female cases a positive correlation was seen for albumin
only. In men R2 values were 0.058, 0.045 and 0.018 inthe total model, for clinical data and for plasma variables
respectively and the R2 values for women were 0.191,
0.170 and 0.022. Adding homocysteine to the model did
not change the major findings, but in female referents the
correlation between Apo B and diabetes was no longer
significant and in male cases a significant correlation
between Apo B and creatinine was seen.
Discussion
This study on the relationship between apolipoproteins,
B-vitamins, homocysteine and MTHFR is to our know-
ledge the largest, including both men and women. We
have previously reported that homocysteine levels were
positively associated and folate concentrations in plasma
were inversely associated with first myocardial infarction in
this cohort [1]. The associations were seen independently
of each other and of a number of cardiovascular risk
factors, including apolipoprotein levels. No clear risk
relationship was apparent for plasma vitamin B12
concentrations, and vitamin B12, B6 and B2 intake.
As expected, Apo A1 and Apo B showed strong associa-
tions with risk for first myocardial infarction, except the
association with Apo A1 in women where the odds ratio
Table 2 Risk for incident myocardial infarction and p for trend for apolipoprotein quartiles (Q1-Q4)
N Q1a Q2a Q3a Q4a Ptrend
Apo A1
All subjects 1555 1.0 0.74 (0.55-0.98) 0.47 (0.35-0.65) 0.41 (0.30-0.57) <0.001
Adjustedb 1150 1.0 0.79 (0.55-1.13) 0.66 (0.45-0.97) 0.52 (0.35-0.79) 0.001
Adjustedc 1077 1.0 0.77 (0.53-1.11) 0.68 (0.45-1.02) 0.50 (0.33-0.76) 0.001
Men 1105 1.0 0.73 (0.52-1.02) 0.53 (0.36-0.76) 0.42 (0.28-0.61) <0.001
Adjustedb 950 1.0 0.74 (0.50-1.11) 0.63 (0.41-0.97) 0.50 (0.32-0.79) 0.002
Adjustedc 894 1.0 0.71 (0.47-1.07) 0.62 (0.40-0.97) 0.47 (0.30-0.76) 0.002
Women 450 1.0 0.75 (0.44-1.29) 0.36 (0.20-0.67) 0.40 (0.22-0.72) <0.001
Adjustedb 200 1.0 0.81 (0.35-1.90) 0.89 (0.35-2.30) 0.62 (0.22-1.74) 0.425
Adjustedc 183 1.0 0.83 (0.34-2.05) 1.15 (0.41-3.23) 0.61(0.21-1.78) 0.509
Apo B
All subjects 1555 1.0 1.76 (1.25-2.49) 1.69 (1.19-2.41) 3.55 (2.55-4.95) <0.001
Adjustedb 1150 1.0 1.58 (1.02-2.43) 1.75 (1.12-2.74) 3.11 (2.05-4.73) <0.001
Adjustedc 1077 1.0 1.78 (1.13-2.81) 1.65 (1.03-2.65) 3.56 (2.29-5.54) <0.001
Men 1105 1.0 1.54 (1.03-2.30) 1.43 (0.93-2.20) 3.34 (2.29-4.87) <0.001
Adjustedb 950 1.0 1.45 (0.91-2.30) 1.46 (0.89-2.40) 2.91 (1.86-4.55) <0.001
Adjustedc 894 1.0 1.57 (0.97-2.54) 1.35 (0.80-2.26) 3.21 (2.00-5.15) <0.001
Women 450 1.0 2.50 (1.27-4.92) 2.44 (1.27-4.68) 4.13 (2.07-8.25) <0.001
Adjustedb 200 1.0 2.62 (0.71-9.65) 3.82 (1.07-13.60) 3.87 (1.08-13.91) 0.036
Adjustedc 183 1.0 3.86 (0.89-16.81) 4.56 (1.09-19.20) 5.53 (1.32-23.11) 0.024
Apo B/Apo A1
All subjects 1555 1.0 1.48 (1.01-2.16) 2.12 (1.47-3.06) 4.51 (3.19-6.38) <0.001
Adjustedb 1150 1.0 1.25 (0.79-1.96) 1.95 (1.24-3.06) 3.06 (2.01-4.66) <0.001
Adjustedc 1077 1.0 1.39 (0.86-2.23) 2.17 (1.35-3.50) 3.46 (2.22-5.40) <0.001
Men 1105 1.0 1.33 (0.85-2.07) 1.84 (1.20-2.82) 4.14 (2.78-6.16) <0.001
Adjustedb 950 1.0 1.18 (0.72-1.92) 1.71 (1.05-2.76) 2.92 (1.85-4.60) <0.001
Adjustedc 894 1.0 1.24 (0.75-2.07) 1.86 (1.12-3.09) 3.24 (2.00-5.23) <0.001
Women 450 1.0 1.96 (0.94-4.10) 3.07 (1.50-6.28) 5.76 (2.84-11.69) <0.001
Adjustedb 200 1.0 2.80 (0.69-11.40) 6.82 (1.50-31.08) 5.63 (1.50-21.11) 0.010
Adjustedc 183 1.0 3.99 (0.84-18.83) 9.13 (1.67-49.95) 7.09 (1.68-29.88) 0.010
Conditional logistic regression analysis with odds ratio and 95% confidence interval.
aP-Apo A1 quartile limits were for men, 1.27, 1.41, 1.56 and for women, 1.42, 1.60, 1.75 g/L. P-Apo B quartile limits were for men, 0.99, 1.17, 1.31 and for women,
0.96, 1.18 and 1.39 g/L. P-ApoB/Apo A1 ratio quartile limits were for men, 0.686, 0.817, 0.966 and for women, 0.601, 0.733, 0.890; bAdjusted for smoking, systolic
blood pressure, BMI and CRP; cAdjusted for diabetes, smoking, systolic blood pressure, BMI and CRP.
Söderström et al. Lipids in Health and Disease 2013, 12:74 Page 4 of 11
http://www.lipidworld.com/content/12/1/74increased after adjustments and was no longer significant.
Adjusting Apo A1 for folate did not change the significant
findings, which is in line with our previously reported
study [1].
Analyzing over 1500 subjects, from a population
without folate fortification, we found no clear relationship
between plasma tHcy and Apo A1 levels in multiple
regression. In contrast folate was positively associated with
Apo A1 levels in multiple analyses in all men and women,
as well as among male and female referents. This
association was not seen among cases which could be
due to lower statistical power as the beta-values for
male cases and referents are similar (Table 5). It is also
possible that something else interferes in the subjects thatlater develop MI. Vitamin B12 showed an association with
Apo A1 in men, i.e. among male referents.
The MTHFR677C>T polymorphism, a major genetic
determinant of tHcy, showed no association with Apo
A1 levels, with the exception of male referents where an
association was seen for Apo A1 using a recessive
model. The significance of this is unclear. In the multiple
models, the plasma variables and the clinical data had
approximately the same explanatory power on the
variation in Apo A1.
For Apo B levels no association was seen for B-vitamins
in multiple regression models. tHcy had a positive associ-
ation in univariate regression analysis with Apo B among
all women and female referents. Apo B variation among
Table 3 Univariate linear regression versus Apo A1 for men and women separately
Men Women
Variables All Cases Referents All Cases Referents
BMI, kg/m2 0.061 (<0.001) 0.018 (0.005) 0.078 (<0.001) 0.017 (0.022) 0.016 0.010
Age at inclusion, years 0.002 0.005 <0.001 0.030 (<0.001) 0.039 (0.008) 0.027 (0.003)
Diabetes, (yes/no) 0.005 (0.015) 0.005 <0.001 0.006 <0.001 0.035 (0.013)
Systolic BP, mm Hg <0.001 0.003 <0.001 0.011 0.087 (0.004) 0.002
Current smoking, (yes/no) 0.001 <0.001 <0.001 0.024 (0.001) <0.001 0.019 (0.010)
Homocysteine, μmol/L <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
Vitamin B12, pmol/L 0.011 (<0.001) <0.001 0.018 (<0.001) <0.001 <0.001 0.736
Folate, nmol/L 0.023 (<0.001) 0.003 0.026 (<0.001) 0.001 <0.001 <0.001
Creatinine, μmol/L 0.007 (0.005) 0.015 (0.012) 0.003 <0.001 <0.001 −0.004
Albumin, g/L 0.007 (0.004) 0.001 0.005 (0.040) <0.001 <0.001 <0.001
Cystatin-C, mg/L <0.001 0.010 (0.033) <0.001 <0.001 0.010 <0.001
CRP log 0.041 (<0.001) 0.017 (0.006) 0.039 (<0.001) 0.067 (<0.001) 0.055 (0.002) 0.051 (<0.001)
MTHFR 677C>T 0.002 <0.001 0.004 <0.001 <0.001 0.001
677 reca 0.002 <0.001 0.004 (0.048) 0.001 <0.001 0.002
677 domb 0.002 <0.001 0.001 <0.001 0.003 <0.001
MTHFR 1298A>C <0.001 <0.001 <0.001 <0.001 0.006 <0.001
1298 recc <0.001 <0.001 <0.001 <0.001 0.005 <0.001
1298 domd <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
aMTHFR 677 rec: 0 = 677CC and CT, 1 = 677TT (recessive model); bMTHFR 677 dom: 0 = 677CC, 1 = 677CT and TT (dominant model); cMTHFR 1298 rec: 0 = 1298
AA and AC, 1 = 1298 CC (recessive model); dMTHFR 1298 dom: 0 = 1298AA, 1 = 1298 AC and CC (dominant model).
R2 (p-value, if <0.05) is presented.
Söderström et al. Lipids in Health and Disease 2013, 12:74 Page 5 of 11
http://www.lipidworld.com/content/12/1/74women was explained to a higher degree by clinical data
compared to Apo A1.
Previous studies [20,22-25] have reported that increased
plasma tHcy is associated with decreased Apo A1 levels.
Two early studies reported a negative correlation in men
with coronary artery disease [23,27] with 40 and 60 sub-
jects respectively. In a Finnish cohort of about the sameTable 4 Multiple regression models on factors influencing Ap
Apo A1 Men Women
R2 Complete Model 0.144 0.106
Beta SE p Beta SE
Clinical data
BMI −0.014 0.002 <0.001 −0.003 0.004
Age at inclusion 0.003 0.001 0.004 0.001 0.002
Diabetes 0.020 0.059 0.731 0.059 0.129
Systolic BP 0.001 0.000 0.024 0.001 0.001
Current smoking 0.094 0.064 0.143 0.054 0.139
Analytes
Vitamin B12 0.000 0.000 0.016 0.000 0.000
Folate 0.005 0.001 0.001 0.006 0.003
Creatinine −0.001 0.001 0.013 0.002 0.002
CRP log −0.078 0.016 <0.001 −0.124 0.037
Albumin 0.003 0.002 0.110 −0.001 0.002
P-values <0.05 are shown in bold.size as ours, Apo A1 was associated with tHcy in a multi-
variate regression model [22]. Compared to our cohort
their subjects were much younger (24–39 years). They
reported no association between MTHFR and Apo A1
levels which is in agreement with our results. None of the
studies mentioned above included analysis of the major
dietary determinants of tHcy, i.e. plasma folate ando A1 and Apo B levels for all men and women separately
Apo B Men Women
0.058 0.191
p Beta SE p Beta SE p
0.450 0.013 0.003 <0.001 0.007 0.005 0.169
0.603 0.003 0.001 0.031 0.010 0.003 0.001
0.648 −0.056 0.078 0.471 0.165 0.163 0.314
0.112 0.000 0.001 0.915 0.004 0.001 0.001
0.698 −0.005 0.085 0.957 0.428 0.176 0.016
0.476 0.000 0.000 0.401 0.000 0.000 0.810
0.031 −0.002 0.002 0.287 −0.002 0.003 0.486
0.229 0.001 0.001 0.139 0.006 0.002 0.011
0.001 0.019 0.021 0.352 0.032 0.047 0.501
0.474 0.010 0.003 <0.001 0.000 0.003 0.885
Table 5 Multiple regression models on factors influencing Apo A1 levels in referents and cases, respectively separated
in men and women
Referents Men Women Cases Men Women
R2 Complete model 0.140 0.099 0.112 0.078
Beta SE p Beta SE p Beta SE p Beta SE p
Clinical data
BMI −0.015 0.003 <0.001 0.002 0.005 0.739 −0.012 0.003 0.001 −0.006 0.006 0.311
Age at inclusion 0.002 0.001 0.108 0.001 0.003 0.664 0.004 0.002 0.025 0.004 0.004 0.334
Diabetes 0.042 0.077 0.584 −0.082 0.164 0.619 −0.039 0.092 0.675 −0.248 0.231 0.288
Systolic BP 0.001 0.001 0.171 0.001 0.001 0.266 0.002 0.001 0.024 0.001 0.001 0.344
Current smoking 0.097 0.087 0.262 0.069 0.177 0.699 0.054 0.098 0.582 −0.248 0.231 0.288
Analytes
Vitamin B12 0.000 0.000 0.017 0.000 0.000 0.693 0.001 0.001 0.347 0.000 0.000 0.468
Folate 0.004 0.002 0.009 0.007 0.003 0.030 0.004 0.003 0.157 0.002 0.005 0.672
Creatinine −0.001 0.001 0.338 0.000 0.002 0.941 −0.002 0.001 0.008 0.003 0.003 0.223
CRP log −0.081 0.019 <0.001 −0.144 0.049 0.004 −0.067 0.028 0.019 −0.095 0.072 0.192
Albumin 0.002 0.003 0.357 0.000 0.002 0.845 0.005 0.004 0.213 −0.003 0.008 0.722
P-values <0.05 are shown in bold.
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that whole blood folate correlated positively and tHcy
negatively with Apo A1 and HDL when merging cases
and controls (n=210), but no further statistical analysis of
these associations was performed [34]. A large study
(middle aged men, n=2775) with multiple biomarkersTable 6 Univariate linear regression versus Apo B for men an
Men
Variables All Cases Re
BMI, kg/m2 0.028 (<0.001) <0.001 0.0
Age at inclusion, years 0.002 0.005 0.0
Diabetes, (yes/no) <0.001 <0.001 <0
Systolic BP, mm Hg 0.005 (0.010) <0.001 0.0
Current smoking, (yes/no) 0.007 (0.004) <0.001 <0
Homocysteine, μmol/L <0.001 0.006 <0
Vitamin B12, pmol/L <0.001 <0.001 <0
Folate, nmol/L 0.001 <0.001 <0
Creatinine, μmol/L 0.001 0.001 <0
Albumin, g/L 0.005 (0.015) 0.022 (0.003) 0.0
Cystatin-C, mg/L <0.001 0.003 <0
CRP log 0.067 (<0.001) 0.017 (0.006) 0.0
MTHFR 677C>T <0.001 <0.001 <0
677 reca <0.001 <0.001 0.0
677 domb <0.001 <0.001 <0
MTHFR 1298A>C 0.001 0.002 0.0
1298 recc 0.001 0.003 0.0
1298 domd <0.001 0.002 <0
aMTHFR 677 rec: 0 = 677CC and CT, 1 = 677TT (recessive model); bMTHFR 677 dom
AA and AC, 1 = 1298 CC (recessive model); dMTHFR 1298 dom: 0 = 1298AA, 1 = 129
R2 (p-value, if <0.05) is presented.linked to coronary heart disease risk, failed to show
an association between plasma levels of Apo A1 or
HDL and plasma levels of tHcy or folate [31]. They further
analyzed associations with 948 SNPs in 122 candidate
genes. SNPs in the APOA5-A4-C3-A1 gene were
associated with triglycerides, HDL, Apo A1, tHcy andd women separately
Women
ferents All Cases Referents
46 (<0.001) 0.034 (0.002) 0.012 0.035 (0.009)
15 (<0.001) 0.062 (<0.001) <0.001 0.115 (<0.001)
.001 <0.001 <0.001 <0.001
12 (0.002) 0.070 (<0.001) 0.003 0.081 (<0.001)
.001 <0.001 <0.001 <0.001
.001 0.013 (0.009) <0.001 0.021 (0.008)
.001 <0.001 <0.001 <0.001
.001 0.012 (0.012) <0.001 0.019 (0.012)
.001 0.009 (0.028) <0.001 0.033 (0.001)
03 <0.001 <0.001 <0.001
.001 0.007 <0.001 0.005
39 (<0.001) 0.067 (<0.001) 0.055 (0.002) 0.051 (<0.001)
.001 0.004 0.004 <0.001
01 0.001 0.008 <0.001
.001 <0.001 <0.001 <0.001
08 (0.026) <0.001 <0.001 <0.001
09 (0.007) 0.002 0.005 <0.001
.001 <0.001 <0.001 <0.001
: 0 = 677CC, 1 = 677CT and TT (dominant model); cMTHFR 1298 rec: 0 = 1298
8 AC and CC (dominant model).
Table 7 Multiple regression models on factors influencing Apo B levels in referents and cases, respectively separated
in men and women
Referents Men Women Cases Men Women
R2 Complete model 0.068 0.283 0.030 0.131
Beta SE p Beta SE p Beta SE p Beta SE p
Clinical data
BMI 0.015 0.003 <0.001 −0.001 0.006 0.926 0.005 0.005 0.323 0.010 0.008 0.171
Age at inclusion 0.004 0.001 0.001 0.015 0.004 <0.001 0.000 0.002 0.894 −0.003 0.005 0.535
Diabetes −0.002 0.096 0.986 0.490 0.194 0.013 −0.071 0.127 0.576 −0.237 0.265 0.376
Systolic BP 0.000 0.001 0.814 0.004 0.002 0.017 −0.001 0.001 0.242 0.004 0.002 0.037
Current smoking 0.049 0.107 0.649 0.659 0.209 0.002 −0.029 0.134 0.830 0.029 0.283 0.918
Analytes
Vitamin B12 0.000 0.000 0.151 0.000 0.000 0.903 0.000 0.000 0.422 0.000 0.000 0.910
Folate −0.001 0.002 0.633 −0.002 0.004 0.594 −0.001 0.004 0.867 −0.001 0.006 0.927
Creatinine 0.000 0.001 0.853 0.008 0.003 0.008 0.002 0.001 0.057 0.002 0.003 0.491
CRP log 0.027 0.024 0.255 0.033 0.058 0.565 −0.034 0.039 0.384 0.024 0.088 0.785
Albumin 0.009 0.003 0.005 −0.001 0.003 0.621 0.016 0.005 0.003 0.031 0.010 0.004
P-values <0.05 are shown in bold.
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but not homocysteine, was still significantly associated
with that gene. They found no association between
MTHFR and lipids.
A study on heterozygous familial hypercholesterolemia
reported that higher plasma homocysteine levels and
MTHFR 677 TT genotype were associated with lower
HDL plasma values [21]. Consistent with this, results
from a cross-sectional study in a large population, who
had undergone a diagnostic coronary angiography, show
that plasma homocysteine, but not cysteine, correlated
negatively with Apo A1 [25]. Similar findings were
reported in a study with elderly volunteers (n=667, aged
60–85 years) with peripheral arterial disease [20]. They
reported a negative correlation for homocysteine with
Apo A1 as well as with HDL, but found no association for
folate. Vitamin B12 was positively, and methylmalonic
acid negatively associated with Apo A1 in univariate
analysis only. The results of our study do not support
these reported findings. One reason could be that in
contrast to the others studies, the participants in our
study were free from previous history of MI and
stroke. Concurrent disease may influence the results.
This can be exemplified by a study with type 2 diabetic
patients treated with fenofibrate, were baseline HDL and
Apo A1 correlated inversely with homocysteine in both
fenofibrate and placebo groups before treatment [36].
One study in cystathionine β-synthase (Cbs)-deficient mice
suggested that cysteinemia rather than homocysteinemia
is negatively correlated with Apo A1 [37]. Another
study on humans showed a positive correlation between
total cysteine and total cholesterol, and Apo B [30]. They
also reported that taurin was inversely related to HDLcholesterol and Apo A1. No association with homocysteine
was found.
Folate, in the form of 5-methyl tetrahydrofolate, is the
main source of methyl groups used for methylation, for
example by DNA methyl transferases. Thus, one-carbon
metabolism is closely linked to methylation of genes, for
example promotor regions. This epigenetic mechanism
may either silence or activate a gene. We have previously
published data on the effects on CpG island methylator
phenotypes [38]. Altered DNA methylation patterns
in atherosclerosis, both hyper- and hypomethylation,
have been suggested to be secondary to a decrease in
S-adenosyl methionine, the main methyl group donor
which is highly dependent on the availability of folate and
vitamin B12 [39]. One possible link between one-carbon
metabolism and lipid metabolism is folate-dependent
epigenetic effects in genes, such as the modulation of
peroxisome proliferator-activated receptor (PPAR) α
in mouse embryos [40,41]. PPAR α agonists such as
fibrates have been shown to upregulate transcription
of the human Apo A1 gene but the mechanism in
humans is not known [42,43].
Other studies in mice and cells including the modulation
of PPAR α, supports a negative correlation between tHcy
and Apo A1 [27,44]. Also, hyperhomocysteinemia may
inhibit HDL biosynthesis and function by reduced
hepatic Apo A1 protein expression, and increased
HDL-C clearance [24].
A main strength in our study is the design where we
could study subjects that did not have previous MI, stroke
or cancer, at inclusion, with both men and women in the
cohort. These findings are probably representative for the
general population as we only excluded subjects with prior
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those who later did or did not have a first MI. We also
excluded all subjects with lipid lowering drugs. Other
strengths are that we analyzed the B-vitamins folate and
B12, and that the results were not confounded by folate
fortification. A limitation of this study is that lifestyle factors
can be a confounding factor, as healthy eating and exercise
could lead to higher levels of both Apo A1 and folate.
The number of cases may be too low to reveal a
weak association between folate and Apo A1. Not all
subjects were fasting at time of blood sampling. This
may have had an effect on the results, as tHcy may
be influenced by a high methionine meal. However, the
number of subjects that were not fasting was low
and excluding those subjects had no effect on the
associations. As alcohol is known to have impact on
lipoproteins, it is also a limitation that alcohol intake
data was only available for a subset and thus could
not be corrected for [45].
Conclusions
In conclusion, tHcy was not associated with Apo A1 levels
in a large cohort with over 1500 subjects without folate
fortification. Instead, plasma folate, the major dietary
determinant of tHcy, was found to be independently
and positively associated with Apo A1 levels. This
association was seen for both men and women, but
restricted to referents. Those who later developed MI
showed no association with folate. Future studies on
the association between tHcy and endpoints or biomarkers




This was a prospective incident nested case-referent
study within the Northern Sweden Health and Disease
Study Cohort (NSHDSC) [46]. The cohort has been
collected using populations-based methodology: The
Northern Sweden WHO Monitoring of Trends and
determinants in Cardiovascular Disease (MONICA)
study, the Västerbotten Intervention Project (VIP) and
the local Mammography Screening Project (MSP).
MONICA randomly selected and invited 25–74 year old
subjects who participated in four health surveys between
1986 and 1999. The mean participation rate was about
77% [47]. VIP which was initiated in 1985, invited all
subjects to their local primary health care center the year
they turned 30, 40, 50, 60 years (since 1996 at 40, 50 and
60 years of age). The design of VIP was similar to the
MONICA population surveys. Mean participation rate
was approximately 60% and comparisons of social
characteristics between participants and non-participants
have shown little evidence of selection bias [48], implyingthe participants were representative of the population. In
the local Mammography Screening Project(MSP), which
was founded in 1995, all women approximately between
50–70 years were invited to undergo mammography, and
at the same time they were invited to donate a blood
sample to the Northern Sweden Medical Biobank [46].
Mean participation in mammography screening has been
85% and participation in screening and donation of blood
sample has been 33%. There has been no mandatory folate
fortification in Sweden.
All participants were invited to complete a stan-
dardized questionnaire including life-style factors
and subjects were interviewed by a trained nurse for
all sorts of medication used. Those participating
within the MSP completed a short questionnaire.
The standardized questionnaires were used to calculate
alcohol intake (g/day). This information was only available
for a subset (170 male and 35 female cases and 367 male
and 78 female referents) and thus not included in
the analysis.
In the study, all cases with fatal and non-fatal first MI
and suspected fatal MI (ICD-9 410, ICD-10 I21-3),
between the ages of 25 and 64 years and from 1 January
1985 to 31 December 1999 were included. The case
identification was done in a standardized manner in
accordance with WHO and MONICA criteria [47].
Using Swedish personal identity numbers as the link-
age variable, hospital records, general practitioner´s
reports, death certificates, and autopsy reports were
screened. For cases, exclusion criteria were, previous
MI, stroke or cancer diagnosis within 5years prior to
and 1 year after MI. Two matching referents for each
case were randomly selected. Referents were excluded for
MI, stroke, cancer or death prior to the time of diagnosis
of the index case.
Diabetes was defined as fasting plasma glucose ≥ 7.0
mmol/L and/or post-load plasma glucose ≥ 11.0 mmol/L
(12.2 mmol/L in VIP, in which capillary plasma was
used) and/or self-reported diabetes. For classification as
non-diabetic, measurement of fasting or post-load
glucose was required. Fasting glucose and/or 2-hour oral
glucose load tests were available for 444 cases and 855
referents. Patients with lipid-lowering drugs (n=9) were
excluded. Hypertension was defined as systolic blood
pressure (BP) ≥ 140 mm Hg and/or diastolic blood
pressure ≥ 90 mm Hg and/or use of medication to
lower blood pressure. Current smoking was defined
as daily smoking, excluding non-, previous-, and non-
daily smokers. Information about pre- or postmeno-
pausal status among women was not available in this
study. Postmenopausal woman was therefore defined
as ≥ 56 years of age at inclusion (n=311), the age
when 95% are estimated to be in menopausal status
in a Swedish material [49]. According to this study
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few percent postmenopausal women. This group was
small (n=24) in our study.
All participants have given written consent. The
Research Ethics Committee of Umeå University, Umeå
and the National Computer Data Inspection Board have
approved the data handling procedures.
Blood sampling and laboratory procedures
Peripheral venous blood samples were collected in
evacuated test tubes containing heparin, in MONICA
and VIP, generally in the morning after at least four
hours fasting. In MSP blood samples were collected
throughout the day. In the study, 66.9% (n=762) of
the men had fasted for more than 8 hours and 15.7%
(n=179) had fasted between 4–8 hours, while 3.6%
(n=41) had fasted for less than 4 hours. Information
about fasting status was missing for 13.8% (n=157) of
the men. Corresponding fasting status for women
was, 36.5% (n=168), 14.8% (n=68) and 43.0% (n=198).
Information about fasting status was missing for 5.7%
(n=26) of the women.
Plasma was aliquoted after centrifugation at 1500g for 15
minutes. Until analysis they were stored frozen at −80ºC.
Plasma specimens were analyzed in triplets of one
case and two referents. To avoid systemic bias and
interassay variability the position for the case was
varied in random and the laboratory staff were blinded to
case and referent status.
Apo A1 and Apo B were analyzed with immune
turbidimetry on a Hitachi 911 multianalyzer with reagents
from DAKO (Copenhagen, Denmark). Homocysteine
was analyzed in batch with fluorescence polarization
immunoassay on an IMx® unit (Abbott Laboratories, IL,
USA). P-B12 and P-folate were analyzed in batch using
DPC® Solid Phase No Boil Dualcount radio assay
(Diagnostic Products Corporation, CA, USA). Creatinine,
albumin and cystatin C were analyzed with a Hitachi 911
multianalyzer, creatinine (Crea plus, enzymatic method)
with kits from Roche/Boehringer (Mannheim, Germany).
Albumin was analyzed with immune turbidimetry and
Cystatin C with an immunological method, both with
reagents from DAKO (Copenhagen, Denmark). C-reactive
protein (CRP) was analyzed with an automated method,
IMMULITE 1 (Diagnostic Products Corporation, Los
Angeles, CA, USA). Analyses below were analyzed in batch
and thus intra-assay coefficients of variation are presented.
For Apo A1 coefficients of variation (CV:s) were 0.96% and
0.61% at concentrations 0,91 and 1,65 g/L, respectively and
for Apo B 1.21% and 0.62% at concentrations 0.47
and 0.81 g/L, respectively. Homocysteine had CV:s of
2.7% and 1.9% at concentrations 13.1 μmol/L and
25.7 μmol/L respectively. P-folate had CV:s of 15.8%
and 12.1% at concentrations 7.3 mol/L and 30.4nmol/L, respectively and P-B12 16.5% and 10.4% at
the concentrations of 263 pmol/L and 1001 pmol/L.
For control samples, for creatinine CV:s were 1.59%
and 3.21% at concentrations 84 and 367 μmol/L
respectively, for albumin 0.89% and 2.25% at 38.0 g/L
and 64.3 g/L and for Cystatin C 2.90% and 1.20% at
1.12 and 4.59 mg/L. For CRP the interassay coefficient of
variation was <6%.
MTHFR genotyping was performed by the TaqMan
allelic discrimination method, using Minor Groove
Binder (MGB) probes. TaqMan assays and reagents were
from Applied Biosystems (Foster City, CA, USA). The
PCR reactions were performed on GeneAmp PCR
system 9700, PCR programs (Assay-on- Demand, ABI)
at the Center for Genome Research, Umeå University
and the PCR products were analyzed on the ABI PRISM
7900HT Sequence Detection System.
Statistical analysis
Calculations were performed using IBM SPSS Statistics
version 19.0 (IBM Corporation, New York, NY, USA).
Hardy-Weinberg equilibrium was calculated, based on
the χ2-test.
To compare baseline characteristics and study vari-
ables for cases and referents T-test and Chi-square
test for independence were used for continues and
categorical variables respectively. Plasma apolipopro-
tein quartile limits, based on referents, were separ-
ately calculated for men and women and treated as
categorical variables, except when testing for trend,
where they were included as continuous linear vari-
ables in the regression analyses. Odds ratios (OR) for
disease and 95% confidence intervals (CI) were calcu-
lated by conditional logistic regression. Adjustment
was done only for folate and with two other models
both including smoking, systolic blood pressure, BMI
and CRP but with and without diabetes. Missing
values were treated as missing.
To find factors influencing Apo A1, linear regres-
sion analysis was performed. Normal distribution
could not be applied for CRP in our population and
instead transformation was done to logarithmic values. In
univariate linear regression MTHFR genotypes were
coded as follows: one model using the three outcomes
coded 0,1,2; one recessive model (wild type and heterozy-
gote mutant v.s. homozygote mutant ) the other, domin-
ant model (wild type v.s. heterozygote mutant and
homozygote mutant).
Analytes and genotypes that were non-significantly
(p<0.05) associated with apolipoproteins in univariate
analysis of variance were excluded in the multiple
regression models. An exception was homocysteine
were we wanted to test the hypothesis regardless the
result in univariate analysis.
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